Skip to content

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Cumulus Cell mRNA Analysis as Oocyte Quality Marker in the Fertility Lab in a Prospective Single-center Study for rFSH Stimulated Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03663868
Enrollment
100
Registered
2018-09-10
Start date
2018-08-14
Completion date
2021-08-31
Last updated
2018-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Brief summary

Performing an additional non-invasive oocyte diagnostic test based on cumulus cell gene expression could improve the outcome of the ART cycle for rFSH stimulated patients

Interventions

DIAGNOSTIC_TESTCC-Test

Classification of the oocyte/embryo based on the gene expression pattern observed in the cumulus cells

Sponsors

Universitair Ziekenhuis Brussel
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
No minimum to 40 Years
Healthy volunteers
No

Inclusion criteria

* scheduled for intracytoplasmatic sperm injection (ICSI) and single (or double) embryo transfer on day 3 * patients down regulated with gonadotropin-releasing hormone (GnRH) antagonist and stimulated with recombinant Follicle Stimulating Hormone (FSH) * undergoing first or second IVF or ICSI cycle with transfer * Body Mass Index (BMI) between 17 and 33 * regular menstrual cycle (between 24 and 35 days)

Exclusion criteria

* smokers (\> 10 cigarettes per day) * patients requesting Pre-implantation Genetic Diagnosis (PGD) * patients with polycystic ovary syndrome (PCOS), or severe endometriosis (AFS stage 3-4) * couples where the partner has an extremely low sperm count i.e.: extreme oligo-astheno-teratozoospermia (OAT) (\< 100.000/ml) or scheduled for testicular sperm extraction (TESE) * results of eventual preceding cycles may not indicate a known genetic disease, or low ovarian response or an oocyte maturation defect

Design outcomes

Primary

MeasureTime frameDescription
Clinical pregnancy as observed by ultrasound2 months after embryo transferThis observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database

Secondary

MeasureTime frameDescription
Positive beta-hCG pregnancy as observed by serum analysis12-17 days after embryo transferThis observation is routinely performed by the treating physician for every patient undergoing standard ART treatment and is thus available from the fertility center database
Live birth by questionnaireat least 9 months after embryo transferThis observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database. This measurement does not include a scale, there is either a child born or not. The date of delivery and the gender of the child are asked together with eventual complications.
Cumulative pregnancy by ultrasound (for pregnancy follow-up) and questionnaire (for live birth follow-up) (see outcome 1 and 3)2 years after embryo transferThis is the compilation of the data gathered in outcome 1 and 3 for eventual consecutive cycles. This observation is routinely performed by the study nurses of the fertility center for every patient undergoing standard ART treatment and is thus available from the fertility center database

Countries

Belgium

Contacts

Primary ContactInge Van Vaerenbergh, PhD
inge.vanvaerenbergh@uzbrussel.be+32 2 477 46 45
Backup ContactTom Adriaenssens, MSc
tom.adriaenssens@uzbrussel.be+32 2 477 46 45

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026